Suchergebnisse - "Dreyling, Martin"

PubPharm (564)

1

Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma : ELARA trial update

enthalten in: Blood | 2024

von Dreyling, M. | Fowler, N. | Dickinson, M. | +37

2

Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma : durable responses and treatment-free remissions

enthalten in: Blood | 2024

von Handunnetti, S. | Anderson, M. | Burbury, K. | +17

3

Precision hematology : Navigating the evolution of diagnostic classifications in the era of globalized medicine

enthalten in: HemaSphere | 2024

von Macintyre, E. | Döhner, K. | Grønbæk, K. | +5

4

B-cell non-Hodgkin lymphomas

enthalten in: Lancet (London, England) | 2024

von Silkenstedt, E. | Salles, G. | Campo, E. | +1

5

Rituximab, gemcitabine and oxaliplatin in relapsed or refractory indolent and mantle cell lymphoma : results of a multicenter phase I/II-study of the German Low Grade Lymphoma Study Group

enthalten in: Annals of hematology | 2024

von Scheubeck, G. | Hoffmann, M. | Jurinovic, V. | +13

6

Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma : Results From the European Mantle Cell Lymphoma Elderly Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Hoster, E. | Delfau-Larue, M. | Macintyre, E. | +15

7

Follikuläre Lymphome – Therapierealität an der Medizinischen Klinik III im Klinikum der Universität München (LMU Klinikum) : eine retrospektive Untersuchung zur Diagnostik und Therapie follikulärer Lymphome im Zeitraum 1997 – 2016

Erschienen: Dissertation, München, Ludwig-Maximilians-Universität, 2024

von Kirchsteiger, B. | Dreyling, M.

8

Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma

enthalten in: Leukemia & lymphoma | 2024

von Hess, G. | Dreyling, M. | Oberic, L. | +22

9

The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma - a randomized, open-label phase III trial of the European mantle cell lymphoma network

enthalten in: ResearchSquare.com | 2023

von Fischer, L. | Jiang, L. | Dürig, J. | +28

10

Combined treatment with crizotinib and temsirolimus is an effective strategy in mantle cell lymphoma and can overcome acquired resistance to temsirolimus

enthalten in: Hematological oncology | 2023

von Moosburner, M. | Alibegovic, L. | Hasselmann, K. | +7

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[57]